Alpha Tau Medical Ltd(DRTS)

Biotechnology · Jerusalem, JM

$14.68-0.21 (-1.40%)

Delayed quote: Oct 6, 2026, 11:49 AM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T15:51:16.064Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:51:16.064Z.

Quote observation: 2026-10-06T15:49:59.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,326,128,381
Total debt · period ending 2026-06-30: 15,152,000
Cash · period ending 2026-06-30: 22,993,000
TTM revenue · period ending 2026-06-30: 0

FMP input reference: d0cade57d6bc8828dc71ac364ddc44a4328d7c948fb2699a56d4eea8e3f6e5b7

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DRTS EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

DRTS Competitors' EV/Sales Ratio

DRTS

Alpha Tau Medical Ltd

Current

Market Cap

$1.33B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMER

Omeros Corporation

vs DRTS

Market Cap

$1.35B

EV/Sales Ratio

37.35x

TTM Avg

98.44x

3Y Avg

98.44x

5Y Avg

78.47x

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs DRTS

Market Cap

$1.37B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KARD

Kardigan, Inc.

vs DRTS

Market Cap

$1.30B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORIC

ORIC Pharmaceuticals, Inc.

vs DRTS

Market Cap

$1.25B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRA

Kailera Therapeutics, Inc.

vs DRTS

Market Cap

$1.41B

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBX

Inhibrx Biosciences Inc.

vs DRTS

Market Cap

$1.41B

EV/Sales Ratio

N/A

TTM Avg

781.47x

3Y Avg

902.36x

5Y Avg

638.00x

PNTG

The Pennant Group, Inc.

vs DRTS

Market Cap

$1.42B

EV/Sales Ratio

1.72x

TTM Avg

1.63x

3Y Avg

1.71x

5Y Avg

1.70x

CRON

Cronos Group Inc.

vs DRTS

Market Cap

$1.23B

EV/Sales Ratio

3.38x

TTM Avg

1.73x

3Y Avg

1.52x

5Y Avg

2.69x

OMDA

Omada Health

vs DRTS

Market Cap

$1.23B

EV/Sales Ratio

3.24x

TTM Avg

3.34x

3Y Avg

3.78x

5Y Avg

3.78x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Alpha Tau Medical Ltd (DRTS)	$1.33B	N/A	N/A	N/A	N/A
Omeros Corporation (OMER)vs ›	$1.35B	37.35x	98.44x	98.44x	78.47x
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.37B	N/A	N/A	N/A	N/A
Kardigan, Inc. (KARD)vs ›	$1.30B	N/A	N/A	N/A	N/A
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.25B	N/A	N/A	N/A	N/A
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.41B	N/A	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.41B	N/A	781.47x	902.36x	638.00x
The Pennant Group, Inc. (PNTG)vs ›	$1.42B	1.72x	1.63x	1.71x	1.70x
Cronos Group Inc. (CRON)vs ›	$1.23B	3.38x	1.73x	1.52x	2.69x
Omada Health (OMDA)vs ›	$1.23B	3.24x	3.34x	3.78x	3.78x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics